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Background: Multiparametric magnetic resonance imaging (mpMRI) targeted prostate biopsy increases 
the diagnostic accuracy of clinically significant prostate cancer (PCa). Currently there is no consensus on 
which type of MRI-targeted biopsy performs better in a given setting. In this study, we aimed to compare 
the detection rate of (clinically significant) PCa by MRI cognitive targeted biopsy (COG) and in-bore MRI-
targeted biopsy (IB) techniques for naïve prostate biopsy patients in China.
Methods: Our study included 85 men from Beijing United Family Hospital and Clinics and 88 men from 
Beijing Hospital, National Center of Gerontology. All men had no history of prostate biopsy, undergoing 
mpMRI scan due to elevated PSA and/or abnormal DRE. The men in Beijing United Family Hospital group 
received COG plus systematic biopsy. The men in Beijing Hospital group only received IB.
Results: The median age in COG and IB group was 63.0 years and 70.0 years (P<0.01). The median PSA 
was 7.4 and 6.8 ng/mL in COG and IB group respectively (P=0.124). The detection rate of PCa was 36.5% 
by COG and 52.3% by IB (P=0.037). The detection rate of clinically significant PCa (Gleason score ≥7) 
was 23.5% and 29.5% by COG and IB (P=0.371) respectively. In COG group, combination biopsy (COG 
+ systematic biopsy) achieved improved PCa (42.4%) and clinically significant PCa (28.2%) detection rate 
compared with COG alone. However, there was no difference in overall PCa and clinically significant PCa 
detection between combination biopsy and IB. 
Conclusions: IB had a higher rate of overall PCa detection compared with COG, but the two approaches 
did not differ significantly in the detection of clinically significant PCa. There was no significant difference 
in detection rate of PCa and clinically significant PCa between the combination biopsy and IB.
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Introduction
The introduction of PSA testing and subsequent transrectal 
ultrasound (TRUS)-guided systematic prostate biopsy 
led to overdiagnosis and overtreatment of PCa (1,2). The 
technique of multiparametric magnetic resonance imaging 
(mpMRI) can increase the sensitivity of PCa imaging 
and MRI-targeted biopsy improves the detection rate for 
clinically significant PCa (Gleason score ≥7) as compared 
to the conventional TRUS-guided biopsy (3-6). MRI 
cognitive targeted biopsy (COG), in-bore MRI-targeted 
biopsy (IB) and MRI-ultrasound fusion biopsy are the three 
currently used techniques of MRI-targeted biopsy. There 
are advantages and disadvantages to each technique and 
it remains unknown which technique is optimal for MRI-
targeted biopsy (7). 
Most of the studies on the performance of mpMRI 
and additional biopsy techniques come from Europe. The 
use of mpMRI and targeted biopsy was introduced in the 
guidelines of EAU initially only for men having to undergo 
a repeat biopsy. It is only recently that this changed to the 
recommendation to perform mpMRi in all men eligible for 
biopsy (8). In this study, initiated already in 2015 we present 
data of mpMRI and biopsy outcome from two medical 
centers in China using COG + systematic biopsy and the IB 
approach for biopsy naïve men, and compare the detection 
rate of PCa and clinically significant PCa between the two 
biopsy approaches. 
Methods
Study population and mpMRI protocol
From October 2015 to May 2018, a total of 85 men from 
Beijing United Family Hospital and Clinics, Beijing, 
China and 88 men from Beijing Hospital, National Center 
of Gerontology, Beijing, China underwent mpMRI and 
subsequent MRI-targeted biopsy due to an elevated PSA 
(≥4 ng/mL) and/or abnormal DRE. All men were not 
previously biopsied. All men included in our study had an 
abnormal MRI defined as PI-RADS ≥2 lesions with PCa 
suspicion found on MRI according to Prostate Imaging 
Reporting and Data System (PI-RADS) 2.0 version. 
Men from Beijing United Family Hospital and Clinics 
received COG biopsy and additional systematic biopsy. 
COG was implemented using TRUS to target the 
suspicious lesions identified at mpMRI. A 1.5T system 
(GE Healthcare) was used and the prostate MRI protocols 
included T1WI, triplanar (axial, sagittal and coronal) 
T2WI, diffusion weighted imaging (DWI) and dynamic 
contrast-enhanced imaging (DCE) by using an 8-channel 
phased-array coil. The operator performs 2 cores in each 
lesion by transperineal approach and the median number of 
targeted biopsy cores was 4 (IQR 2–7). The transperineal 
systematic biopsy was performed with a TRUS-guided 
approach using a median number of 12 cores (IQR 12–16). 
In the Beijing Hospital group, MRIs were performed 
on a 3.0T MR system (GE Healthcare, M750) with 
16-channel pelvic phased-array coil. All the men underwent 
IB only, which was applied using system DynaCAD for 
ProstateDyna TRIM. The operator performs the transrectal 
biopsy and confirms the localization of needle based on the 
real-time MRI. Usually, 2 cores were sampled from each 
suspicious lesion. The median number of cores was 4 (IQR 
2–6). 
Statistical analysis
The Mann-Whitney test was performed to compare patient 
characteristics between the two biopsy approaches. The 
Chi-square test was used to compare the distribution of 
PI-RADS score and detection rate of PCa (and clinically 
significant PCa, defined as Gleason ≥7) between the two 
biopsy approaches. A P value less than 0.05 was considered 
statistically significant. Statistical analyses were performed 
by using SPSS for Windows (Version 21.0, IBM Corp 
Armonk, NY, USA). The sensitivity of MRI-targeted biopsy 
(systematic biopsy) was calculated as the number of positive 
MRI-targeted biopsy (systematic biopsy) results divided by 
the total number of cancers detected.
Results
Patient characteristics
The characteristics of the study population are shown in 
Table 1. In the COG group of 85 men, the median age was 
63.0 years (IQR 58.5–70.0) and the median PSA value was 
7.4 ng/mL (IQR 5.8–10.2). The PI-RADS score of the 
dominant lesion was 2 in 10 (11.8%), 3 in 31 (36.5%), 4 in 
28 (32.9%) and 5 in 16 (18.8%) men respectively. 
In the IB group of 88 men, the median age and PSA 
value was 70.0 (IQR 65.0–75.0) years and 6.8 (IQR 4.5– 
9.7) ng/mL respectively. The PI-RADS was 2 in 7 (8.0%), 3 
in 26 (29.5%), 4 in 47 (53.4%) and 5 in 8 (9.1%) men. 
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Table 1 Patient characteristics
COG (n=85) IB (n=88) P
Age (year), median (IQR) 63.0 (58.5–70.0) 70.0 (65.0–75.0) <0.010
PSA (ng/mL), median (IQR) 7.4 (5.8–10.2) 6.8 (4.5–9.7) 0.124
PI-RADS, n (%) 0.708
2 10 (11.8) 7 (8.0)
3 31 (36.5) 26 (29.5)
4 28 (32.9) 47 (53.4)
5 16 (18.8) 8 (9.1)
PSA, prostate specific antigen; IQR, interquartile range; COG, MRI cognitive targeted biopsy; IB, in-bore MRI targeted biopsy; PI-RADS, 
Prostate Imaging Reporting and Data System.
Table 2 Detection rate of PCa and clinically significant PCa by COG and IB alone 
COG (n=85), MRI-targeted biopsy IB (n=88), MRI-targeted biopsy P
PCa (%) 31 (36.5%) 46 (52.3%) 0.037
Clinically significant PCa  
(% of total and % of PCa)
20 (23.5%, 64.5%) 26 (29.5%, 56.5%) 0.371
COG, MRI cognitive targeted biopsy; IB, in-bore MRI targeted biopsy; PCa, prostate cancer.
Table 3 Detection rate of PCa and clinically significant PCa by COG plus systematic biopsy and IB 
COG (n=85), combined biopsy IB (n=88), MRI-targeted biopsy P
PCa (%) 36 (42.4%) 46 (52.3%) 0.191
Clinically significant PCa  
(% of total and % of PCa)
24 (28.2%, 66.7%) 26 (29.5%, 56.5%) 0.849
COG, MRI cognitive targeted biopsy; IB, in-bore MRI targeted biopsy; PCa, prostate cancer.
Detection rate of PCa and clinically significant PCa in the 
two groups
In the COG group, COG alone detected 31 cases of 
PCa (36.5%), of which 20 (23.5%) cases were clinically 
significant PCa. Meanwhile, IB detected significantly more 
cases of PCa [N=46 (52.3%), P=0.037] but a comparable 
percentage of clinically significant PCa cases [N=26 (29.5%), 
P=0.371, Table 2].
In the COG group, combination biopsy (COG + 
systematic biopsy) detected 36 (42.4%) cases of PCa, 
including 24 (28.2%) cases of clinically significant PCa. The 
detection rate of overall PCa, clinically significant PCa was 
not statistically different between the COG combination 
biopsy and the IB (Table 3).
Sensitivity of COG and Systematic biopsy in the COG group
In the COG group, COG alone detected 31 PCa of the 
total of 36 PCa cases, including 20 clinically significant PCa 
of the total of 24 clinically significant PCa cases. Systematic 
biopsy detected 28 PCa cases including 17 clinically 
significant PCa cases. The sensitivity of the systematic 
biopsy alone was 0.78 (28/36) for PCa and 0.71 (17/24) for 
clinically significant PCa. Compared to systematic biopsy 
alone, COG alone achieved superior sensitivity for both 
PCa [0.86 (31/36)] and clinically significant PCa [0.83 
(20/24)] (Table 4).
246 Zhang et al. Comparison of MRI cognitive biopsy and in-bore biopsy in Asian men
  Transl Androl Urol 2020;9(2):243-249 | http://dx.doi.org/10.21037/tau.2020.02.20© Translational Andrology and Urology. All rights reserved.
Discussion
MRI-targeted biopsy has shown great potential to improve 
diagnostic accuracy of clinically significant PCa in multiple 
studies (3-6,9-12). However, the detection rate of PCa and 
clinically significant PCa varies among different studies and 
techniques (13-15). It is still controversial which technique 
is preferred for MRI-targeted biopsy. Performance is most 
likely highly dependent on experience of both radiologist 
and urologist. In addition, availability of equipment (i.e., 
availability of resources) will also play an important role in 
which approach is being used. 
In a systematic review and meta-analysis, 43 studies 
were included and the three currently used techniques were 
compared (16). It was shown that for overall PCa detection, 
there was significant advantage of using of IB compared 
with COG, however, for clinically significant PCa, there 
was no significant advantage in the performance of any 
one technique. In our study, for overall PCa, IB showed a 
significantly higher detection rate as compared to COG. 
For clinically significant PCa detection, COG and IB did 
not differ significantly, making our findings consistent with 
the meta-analysis (16). 
In an Australian study, 482 men with PI-RADS 3−5 
lesions were included with the aim to compare IB with 
COG (transrectal and transperineal) (17). The study showed 
that there was no significant difference in PCa detection 
among IB, transperineal COG and transrectal COG in 
PI-RADS 3 (48.9%, 40.0%, 44.4%), PI-RADS 4 (73.2%, 
81.0%, 85.0%) or PI-RADS 5 (95.2, 92.0%, 95.0%) lesions. 
For clinically significant PCa, the detection rate also did not 
differ between the three techniques in PI-RADS 3 (42.2%, 
30.0%, 33.3%), PI-RADS 4 (66.8%, 66.0%, 80.0%) or PI-
RADS 5 (90.5%, 89.8%, 90.0%) lesions. 
As is known, one of the main concerns for IB is 
the cost of the procedure. It is still a relatively new 
technique, requiring special MR compatible equipment 
and demagnetization of the biopsy gun and related 
instruments resulting in extra costs. In a Dutch study, the 
cost-effectiveness was compared among TRUS systematic 
biopsy, IB and MRI-Ultrasound fusion biopsy. It showed 
that MRI-TRUS fusion biopsy is cost-effective compared 
with TRUS systematic biopsy. However, only if the 
sensitivity of IB for clinically significant PCa is at least 
89%, IB would be the most cost-effective strategy (18). In 
our study, the sensitivity for clinically significant PCa was 
83% by IB, and one could question cost effectiveness. With 
the current available data on the additional value of an IB 
approach, the requirements for successful implementation 
of the IB technique, especially for those regions with limited 
health care expenditures, is unlikely. 
Another point of concern with the IB approach is that 
the procedure is relatively time consuming. One study 
reported that the mean duration was 55 min (19). Generally, 
during the procedure a systematic biopsy is not performed 
mainly due to the time and expense required for each biopsy 
in the MRI magnet environment (20). 
Compared to MRI targeted biopsies, the systematic 
biopsy has been shown to increase cancer detection 
rates (21). Also, in the COG group of our study, if only 
COG would have been performed, 5 (13.9%, 5/36) cases 
of PCa including 4 (16.7%, 4/24) clinically significant PCa 
would have been missed. In contrast, if only systematic 
biopsy was performed, 8 (22.2%, 8/36) cases of PCa 
would have been missed and 7 (29.2%, 7/24) of those were 
clinically significant PCa. 
This complementary effect of the two biopsy approaches 
is confirmed by data from a French study of 555 men with 
suspicion of PCa, where all the men underwent 10–12 cores 
systematic biopsy plus two cores COG. Among 151 men 
with positive MRI, combination biopsy detected 71.8% 
tumors (252/351), which was higher than COG (67.2%, 
236/351) or systematic biopsy alone (68.4%, 240/351) 
alone (22). A Japanese study also showed that systematic 
biopsy missed 34.6% of PCa (18 of 52) compared with 
Table 4 Sensitivity of COG and Systematic biopsy in the COG group
COG biopsy (PCa/Cs PCa)
Systematic biopsy
Total (N=85)
Positive Negative
Positive 23/13 8/7 31/20
Negative 5/4 49/61 54/65
Total (N=85) 28/17 57/68
COG, MRI cognitive targeted biopsy; PCa, prostate cancer; CS PCa, clinically significant prostate cancer.
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13.5% (7 of 52) for the MRI-targeted biopsy (23). A 
recently published meta-analysis indicated that MRI-
targeted biopsy combined with systematic biopsy maximized 
PCa detection as compared to MRI-targeted biopsy or 
systematic biopsy alone in men on active surveillance (24). 
It is interesting to note that in one study the shape and 
size of suspicious lesion on mpMRI was compared with 
the specimen of localized PCa after radical prostatectomy. 
It showed that the mean pathological tumour volume was 
three-times greater than the mean region of interest volume 
indicated on mpMRI (P<0.001) and the tumour diameter 
was significantly underestimated by an average of 11 mm, 
with the tumour extending beyond the region of interest 
on all anatomical axes (25). The authors suggested that 
underestimation of tumour volume may be compensated for 
during the biopsy process by taking additional cores outside 
each suspicious lesion, which indicated that only performing 
MRI-targeted biopsy may not adequate enough. Another 
study revealed that lower MRI lesion volumes, lesion 
density, and PI-RADS score were significantly associated 
with PCa detected by systematic biopsy but missed by 
targeted biopsy (26). 
The European Association of Urology revised the 
guidelines in 2019, advised to perform a MRI scan even 
for initial biopsy patient and to provide subsequent MRI-
targeted biopsy and systematic biopsy for PI-RADS ≥3 
lesions. It is interesting to note that in our study, IB alone 
achieved mildly higher no statistically significant PCa and 
clinically significant PCa detection rate than combination 
biopsy. In a recently published multicenter, randomized 
study, 500 naïve biopsy men with suspicion of PCa were 
assigned to undergo MRI, with or without targeted biopsy, 
or transrectal systematic biopsy. It demonstrated that the 
clinically significant PCa detection rate was 38% in MRI-
targeted biopsy group and 26% in systematic biopsy group 
(P=0.005) (27). This is the first study indicating that next 
to MRI targeted biopsy, systematic biopsy might not be 
necessary. Until these data are confirmed in additional 
studies omitting systematic biopsy remains controversial. 
The strengths of our study include the fact that the 
two cohorts were closely matched in demographics 
and disease characteristics. There were no significant 
differences between the two group in terms of PSA level 
and distribution of PI-RADS score, and all men in this 
study were not previously biopsied. In addition, all patients 
were sampled from two tertiary hospitals with high skills 
in prostate MRI image acquisition and interpretation. In 
addition, the urologists had ample experience in systematic 
and MRI-targeted biopsy. 
Our study is limited by its retrospective nature. The 
patients came from two institutions with different MR 
equipment and the MRI images were reviewed by different 
radiologists. Additionally, the two groups differed in 
median age even these are consecutive patients. However, 
there were no differences in PSA level and PI-RADS score 
between groups. Second, the sample size was relatively 
small in this study, 85 and 88 men were included in the 
two cohorts. Third, our follow-up is limited after prostate 
biopsy. Data from those patients referred to repeat biopsy 
remains absent and the final pathology results from radical 
prostatectomy specimens are still limited. Furthermore, in 
some patients, bias may have been caused by the relatively 
low number of MRI- targeted biopsy cores for the sampled 
PCa volume. 
Conclusions
In this Asian population where also men scheduled for 
initial biopsy underwent mpMRi and targeted biopsy, there 
were no significant difference in the detection rate of PCa 
and clinically significant PCa between the combination 
biopsy approach of COG fusion biopsy including 
systematic biopsies and an IB biopsy approach only. A 
combination biopsy might be more cost-effective in our 
setting since there is no need for special equipment using 
the IB biopsy approach. The sensitivity of the combination 
biopsy for the detection of PCa and clinically significant 
PCa was superior as compared to a systematic biopsy 
approach only.
Acknowledgments
Funding: None.
Footnote
Conflicts of Interest: All authors have completed the ICMJE 
uniform disclosure form (available at http://dx.doi.
org/10.21037/tau.2020.02.20). The authors have no 
conflicts of interest to declare.
Ethical Statement: The authors are accountable for all 
aspects of the work in ensuring that questions related 
to the accuracy or integrity of any part of the work are 
appropriately investigated and resolved. The International 
Review Board (IRB) of the Beijing United Family Hospital 
248 Zhang et al. Comparison of MRI cognitive biopsy and in-bore biopsy in Asian men
  Transl Androl Urol 2020;9(2):243-249 | http://dx.doi.org/10.21037/tau.2020.02.20© Translational Andrology and Urology. All rights reserved.
and Clinics (Medical Ethical Committee) approved our 
database/study (UFHIRB.E 2018–0004).
Open Access Statement: This is an Open Access article 
distributed in accordance with the Creative Commons 
Attribution-NonCommercial-NoDerivs 4.0 International 
License (CC BY-NC-ND 4.0), which permits the non-
commercial replication and distribution of the article with 
the strict proviso that no changes or edits are made and 
the original work is properly cited (including links to both 
the formal publication through the relevant DOI and the 
license). See: https://creativecommons.org/licenses/by-nc-
nd/4.0/.
References
1. Schröder FH, Hugosson J, Roobol MJ, et al. Screening 
and prostate-cancer mortality in a randomized European 
study. N Engl J Med 2009;360:1320-8.
2. Schröder FH, Hugosson J, Roobol MJ, et al. Prostate-
cancer mortality at 11 years of follow-up. N Engl J Med 
2012;366:981-90.
3. Siddiqui MM, Rais-Bahrami S, Turkbey B, et al. 
Comparison of MR/ultrasound fusion-guided biopsy with 
ultrasound-guided biopsy for the diagnosis of prostate 
cancer. JAMA 2015;313:390-7.
4. Schoots IG, Roobol MJ, Nieboer D, et al. Magnetic 
resonance imaging-targeted biopsy may enhance the 
diagnostic accuracy of significant prostate cancer detection 
compared to standard transrectal ultrasound-guided 
biopsy: a systematic review and meta-analysis. Eur Urol 
2015;68:438-50.
5. NiMhurchu E, O'Kelly F, Murphy IG, et al. Predictive 
value of PI-RADS classification in MRI-directed 
transrectal ultrasound guided prostate biopsy. Clin Radiol 
2016;71:375-80.
6. Pokorny MR, de Rooij M, Duncan E, et al. Prospective 
study of diagnostic accuracy comparing prostate cancer 
detection by transrectal ultrasound-guided biopsy versus 
magnetic resonance (MR) imaging with subsequent MR-
guided biopsy in men without previous prostate biopsies. 
Eur Urol 2014;66:22-9.
7. Giganti F, Moore CM. A critical comparison of techniques 
for MRI-targeted biopsy of the prostate. Transl Androl 
Urol 2017;6:432-43.
8. EAU Guidelines: Prostate Cancer 2019. Available 
online: https://uroweb.org/guideline/prostate-
cancer/?type=summary-of-changes 
9. Portalez D, Mozer P, Cornud F, et al. Validation of the 
European Society of Urogenital Radiology scoring system 
for prostate cancer diagnosis on multiparametric magnetic 
resonance imaging in a cohort of repeat biopsy patients. 
Eur Urol 2012;62:986-96.
10. Fütterer JJ, Briganti A, De Visschere P, et al. Can 
Clinically Significant Prostate Cancer Be Detected 
with Multiparametric Magnetic Resonance Imaging? 
A Systematic Review of the Literature. Eur Urol 
2015;68:1045-53.
11. Nam RK, Wallis CJ, Stojcic-Bendavid J, et al. A Pilot 
Study to Evaluate the Role of Magnetic Resonance 
Imaging for Prostate Cancer Screening in the General 
Population. J Urol 2016;196:361-6.
12. Meng X, Rosenkrantz AB, Mendhiratta N, et al. 
Relationship Between Prebiopsy Multiparametric 
Magnetic Resonance Imaging (MRI), Biopsy Indication, 
and MRI-ultrasound Fusion-targeted Prostate Biopsy 
Outcomes. Eur Urol 2016;69:512-7.
13. Wysock JS, Rosenkrantz AB, Huang WC, et al. A 
prospective, blinded comparison of magnetic resonance 
(MR) imaging-ultrasound fusion and visual estimation 
in the performance of MR-targeted prostate biopsy: the 
PROFUS trial. Eur Urol 2014;66:343-51.
14. Kasivisvanathan V, Dufour R, Moore CM, et al. 
Transperineal magnetic resonance image targeted prostate 
biopsy versus transperineal template prostate biopsy in the 
detection of clinically significant prostate cancer. J Urol 
2013;189:860-6.
15. Quentin M, Schimmoller L, Arsov C, et al. 3-T in-
bore MR-guided prostate biopsy based on a scoring 
system for target lesions characterization. Acta Radiol 
2013;54:1224-9.
16. Wegelin O, van Melick HH, Hooft L, et al. Comparing 
Three Different Techniques for Magnetic Resonance 
Imaging-targeted Prostate Biopsies: A Systematic Review 
of In-bore versus Magnetic Resonance Imaging-transrectal 
Ultrasound fusion versus Cognitive Registration. Is There 
a Preferred Technique? Eur Urol 2017;71:517-31.
17. Yaxley AJ, Yaxley JW, Thangasamy IA, et al. Comparison 
between target magnetic resonance imaging (MRI) 
in-gantry and cognitively directed transperineal or 
transrectal-guided prostate biopsies for Prostate Imaging-
Reporting and Data System (PI-RADS) 3-5 MRI lesions. 
BJU Int 2017;120 Suppl 3:43-50.
18. Venderink W, Govers TM, de Rooij M, et al. Cost-
Effectiveness Comparison of Imaging-Guided Prostate 
Biopsy Techniques: Systematic Transrectal Ultrasound, 
249Translational Andrology and Urology, Vol 9, No 2 April 2020
  Transl Androl Urol 2020;9(2):243-249 | http://dx.doi.org/10.21037/tau.2020.02.20© Translational Andrology and Urology. All rights reserved.
Cite this article as: Zhang K, Zhang Z, Liu M, Zhu G, 
Roobol MJ. Comparison of clinically significant prostate 
cancer detection by MRI cognitive biopsy and in-bore MRI-
targeted biopsy for naïve biopsy patients. Transl Androl Urol 
2020;9(2):243-249. doi: 10.21037/tau.2020.02.20
Direct In-Bore MRI, and Image Fusion. AJR Am J 
Roentgenol 2017;208:1058-63.
19. Felker ER, Lee-Felker SA, Feller J, et al. In-bore magnetic 
resonance-guided transrectal biopsy for the detection of 
clinically significant prostate cancer. Abdom Radiol (NY) 
2016;41:954-62.
20. Robertson NL, Emberton M, Moore CM. MRI-targeted 
prostate biopsy: a review of technique and results. Nat Rev 
Urol 2013;10:589-97.
21. Ploussard G, Borgmann H, Briganti A, et al. Positive pre-
biopsy MRI: are systematic biopsies still useful in addition 
to targeted biopsies? World J Urol 2019;37:243-51.
22. Haffner J, Lemaitre L, Puech P, et al. Role of magnetic 
resonance imaging before initial biopsy: comparison of 
magnetic resonance imaging-targeted and systematic 
biopsy for significant prostate cancer detection. BJU Int 
2011;108:E171-8.
23. Miyagawa T, Ishikawa S, Kimura T, et al. Real-time 
Virtual Sonography for navigation during targeted prostate 
biopsy using magnetic resonance imaging data. Int J Urol 
2010;17:855-60.
24. Schoots IG, Nieboer D, Giganti F, et al. Is magnetic 
resonance imaging-targeted biopsy a useful addition 
to systematic confirmatory biopsy in men on active 
surveillance for low-risk prostate cancer? A systematic 
review and meta-analysis. BJU Int 2018;122:946-58.
25. Priester A, Natarajan S, Khoshnoodi P, et al. Magnetic 
Resonance Imaging Underestimation of Prostate 
Cancer Geometry: Use of Patient Specific Molds to 
Correlate Images with Whole Mount Pathology. J Urol 
2017;197:320-6.
26. Coker MA, Glaser ZA, Gordetsky JB, et al. Targets missed: 
predictors of MRI-targeted biopsy failing to accurately 
localize prostate cancer found on systematic biopsy. 
Prostate Cancer Prostatic Dis 2018;21:549-55.
27. Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-
Targeted or Standard Biopsy for Prostate-Cancer 
Diagnosis. N Engl J Med 2018;378:1767-77.
